IDT Australia Ltd (IDT) - Net Assets
Based on the latest financial reports, IDT Australia Ltd (IDT) has net assets worth AU$21.89 Million AUD (≈ $15.49 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$36.92 Million ≈ $26.12 Million USD) and total liabilities (AU$15.03 Million ≈ $10.64 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how resilient are IDT Australia Ltd's assets to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | AU$21.89 Million |
| % of Total Assets | 59.28% |
| Annual Growth Rate | 6.11% |
| 5-Year Change | -20.74% |
| 10-Year Change | -49.54% |
| Growth Volatility | 27.67 |
IDT Australia Ltd - Net Assets Trend (1989–2025)
This chart illustrates how IDT Australia Ltd's net assets have evolved over time, based on quarterly financial data. Also explore IDT total assets for the complete picture of this company's asset base.
Annual Net Assets for IDT Australia Ltd (1989–2025)
The table below shows the annual net assets of IDT Australia Ltd from 1989 to 2025. For live valuation and market cap data, see market value of IDT Australia Ltd.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | AU$21.89 Million ≈ $15.49 Million |
-6.63% |
| 2024-06-30 | AU$23.44 Million ≈ $16.59 Million |
-2.90% |
| 2023-06-30 | AU$24.14 Million ≈ $17.08 Million |
-9.33% |
| 2022-06-30 | AU$26.62 Million ≈ $18.84 Million |
-3.59% |
| 2021-06-30 | AU$27.61 Million ≈ $19.54 Million |
+18.53% |
| 2020-06-30 | AU$23.30 Million ≈ $16.48 Million |
-6.85% |
| 2019-06-30 | AU$25.01 Million ≈ $17.70 Million |
-22.94% |
| 2018-06-30 | AU$32.46 Million ≈ $22.96 Million |
-33.65% |
| 2017-06-30 | AU$48.92 Million ≈ $34.61 Million |
+12.78% |
| 2016-06-30 | AU$43.38 Million ≈ $30.69 Million |
+10.64% |
| 2015-06-30 | AU$39.20 Million ≈ $27.74 Million |
+53.44% |
| 2014-06-30 | AU$25.55 Million ≈ $18.08 Million |
-1.84% |
| 2013-06-30 | AU$26.03 Million ≈ $18.42 Million |
-7.49% |
| 2012-06-30 | AU$28.14 Million ≈ $19.91 Million |
-6.13% |
| 2011-06-30 | AU$29.97 Million ≈ $21.21 Million |
-0.56% |
| 2010-06-30 | AU$30.14 Million ≈ $21.33 Million |
-11.90% |
| 2009-06-30 | AU$34.21 Million ≈ $24.21 Million |
+4.11% |
| 2008-06-30 | AU$32.86 Million ≈ $23.25 Million |
+8.13% |
| 2007-06-30 | AU$30.39 Million ≈ $21.50 Million |
+5.92% |
| 2006-06-30 | AU$28.69 Million ≈ $20.30 Million |
-1.56% |
| 2005-06-30 | AU$29.15 Million ≈ $20.62 Million |
+4.51% |
| 2004-06-30 | AU$27.89 Million ≈ $19.73 Million |
+5.60% |
| 2003-06-30 | AU$26.41 Million ≈ $18.69 Million |
+13.55% |
| 2002-06-30 | AU$23.26 Million ≈ $16.46 Million |
+13.62% |
| 2001-06-30 | AU$20.47 Million ≈ $14.48 Million |
+95.27% |
| 2000-06-30 | AU$10.48 Million ≈ $7.42 Million |
+40.47% |
| 1999-06-30 | AU$7.46 Million ≈ $5.28 Million |
+18.27% |
| 1998-06-30 | AU$6.31 Million ≈ $4.47 Million |
+10.42% |
| 1997-06-30 | AU$5.71 Million ≈ $4.04 Million |
+9.24% |
| 1996-06-30 | AU$5.23 Million ≈ $3.70 Million |
+4.95% |
| 1995-06-30 | AU$4.99 Million ≈ $3.53 Million |
+0.52% |
| 1994-06-30 | AU$4.96 Million ≈ $3.51 Million |
+104.41% |
| 1993-06-30 | AU$2.43 Million ≈ $1.72 Million |
+2.93% |
| 1992-06-30 | AU$2.36 Million ≈ $1.67 Million |
+33.92% |
| 1991-06-30 | AU$1.76 Million ≈ $1.25 Million |
-32.31% |
| 1990-06-30 | AU$2.60 Million ≈ $1.84 Million |
+0.42% |
| 1989-06-30 | AU$2.59 Million ≈ $1.83 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to IDT Australia Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 50592.7% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | AU$64.19 Million | 293.27% |
| Other Comprehensive Income | AU$12.74 Million | 58.19% |
| Other Components | AU$1.00 | 0.00% |
| Total Equity | AU$21.89 Million | 100.00% |
IDT Australia Ltd Competitors by Market Cap
The table below lists competitors of IDT Australia Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
TEAM PLC
F:1WQ
|
$12.10 Million |
|
Desenio Group AB
ST:DSNO
|
$12.10 Million |
|
Multi Prima Sejahtera Tbk
JK:LPIN
|
$12.10 Million |
|
Predilife
PA:ALPRE
|
$12.11 Million |
|
Truscott Mining Corporation Ltd
AU:TRM
|
$12.10 Million |
|
Atlantis Yatirim Holding AS
IS:ATSYH
|
$12.09 Million |
|
BTC Digital Ltd.
NASDAQ:BTCT
|
$12.09 Million |
|
Libet S.A.
WAR:LBT
|
$12.09 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in IDT Australia Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 23,441,000 to 21,887,000, a change of -1,554,000 (-6.6%).
- Net loss of 8,063,000 reduced equity.
- Share repurchases of 6,653,000 reduced equity.
- New share issuances of 6,653,000 increased equity.
- Other comprehensive income increased equity by 20,999.
- Other factors increased equity by 6,488,001.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | AU$-8.06 Million | -36.84% |
| Share Repurchases | AU$6.65 Million | -30.4% |
| Share Issuances | AU$6.65 Million | +30.4% |
| Other Comprehensive Income | AU$21.00K | +0.1% |
| Other Changes | AU$6.49 Million | +29.64% |
| Total Change | AU$- | -6.63% |
Book Value vs Market Value Analysis
This analysis compares IDT Australia Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.78x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 3.70x to 0.78x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1989-06-30 | AU$0.01 | AU$0.04 | x |
| 1990-06-30 | AU$0.01 | AU$0.04 | x |
| 1991-06-30 | AU$0.01 | AU$0.04 | x |
| 1992-06-30 | AU$0.08 | AU$0.04 | x |
| 1993-06-30 | AU$0.11 | AU$0.04 | x |
| 1994-06-30 | AU$0.14 | AU$0.04 | x |
| 1995-06-30 | AU$0.14 | AU$0.04 | x |
| 1996-06-30 | AU$0.15 | AU$0.04 | x |
| 1997-06-30 | AU$0.15 | AU$0.04 | x |
| 1998-06-30 | AU$0.18 | AU$0.04 | x |
| 1999-06-30 | AU$0.22 | AU$0.04 | x |
| 2000-06-30 | AU$0.23 | AU$0.04 | x |
| 2001-06-30 | AU$0.42 | AU$0.04 | x |
| 2002-06-30 | AU$0.46 | AU$0.04 | x |
| 2003-06-30 | AU$0.53 | AU$0.04 | x |
| 2004-06-30 | AU$0.56 | AU$0.04 | x |
| 2005-06-30 | AU$0.63 | AU$0.04 | x |
| 2006-06-30 | AU$0.56 | AU$0.04 | x |
| 2007-06-30 | AU$0.61 | AU$0.04 | x |
| 2008-06-30 | AU$0.66 | AU$0.04 | x |
| 2009-06-30 | AU$0.68 | AU$0.04 | x |
| 2010-06-30 | AU$0.66 | AU$0.04 | x |
| 2011-06-30 | AU$0.64 | AU$0.04 | x |
| 2012-06-30 | AU$0.62 | AU$0.04 | x |
| 2013-06-30 | AU$0.54 | AU$0.04 | x |
| 2014-06-30 | AU$0.36 | AU$0.04 | x |
| 2015-06-30 | AU$0.28 | AU$0.04 | x |
| 2016-06-30 | AU$0.21 | AU$0.04 | x |
| 2017-06-30 | AU$0.19 | AU$0.04 | x |
| 2018-06-30 | AU$0.13 | AU$0.04 | x |
| 2019-06-30 | AU$0.10 | AU$0.04 | x |
| 2020-06-30 | AU$0.10 | AU$0.04 | x |
| 2021-06-30 | AU$0.12 | AU$0.04 | x |
| 2022-06-30 | AU$0.11 | AU$0.04 | x |
| 2023-06-30 | AU$0.10 | AU$0.04 | x |
| 2024-06-30 | AU$0.07 | AU$0.04 | x |
| 2025-06-30 | AU$0.05 | AU$0.04 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently IDT Australia Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -36.84%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -40.79%
- • Asset Turnover: 0.54x
- • Equity Multiplier: 1.69x
- Recent ROE (-36.84%) is below the historical average (-0.28%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1989 | 7.53% | 3.55% | 1.19x | 1.78x | AU$-63.90K |
| 1990 | 3.38% | 1.67% | 1.20x | 1.69x | AU$-172.00K |
| 1991 | -47.73% | -21.99% | 1.19x | 1.83x | AU$-1.02 Million |
| 1992 | 8.44% | 5.03% | 1.16x | 1.44x | AU$-36.70K |
| 1993 | 16.08% | 8.76% | 1.26x | 1.46x | AU$147.40K |
| 1994 | 6.72% | 6.98% | 0.79x | 1.22x | AU$-162.90K |
| 1995 | 6.88% | 6.06% | 0.73x | 1.56x | AU$-155.50K |
| 1996 | 9.81% | 6.81% | 0.74x | 1.96x | AU$-10.19K |
| 1997 | 11.05% | 7.27% | 0.79x | 1.91x | AU$59.95K |
| 1998 | 14.13% | 0.00% | 0.00x | 1.97x | AU$260.85K |
| 1999 | 24.96% | 0.00% | 0.00x | 1.95x | AU$1.12 Million |
| 2000 | 28.66% | 19.78% | 0.82x | 1.76x | AU$1.96 Million |
| 2001 | 18.06% | 19.71% | 0.66x | 1.38x | AU$1.65 Million |
| 2002 | 18.15% | 20.22% | 0.64x | 1.41x | AU$1.90 Million |
| 2003 | 15.99% | 16.54% | 0.75x | 1.30x | AU$1.58 Million |
| 2004 | 15.27% | 16.88% | 0.69x | 1.31x | AU$1.47 Million |
| 2005 | 15.34% | 16.84% | 0.71x | 1.28x | AU$1.56 Million |
| 2006 | 12.59% | 14.56% | 0.70x | 1.23x | AU$743.80K |
| 2007 | 17.99% | 20.79% | 0.71x | 1.21x | AU$2.43 Million |
| 2008 | 21.64% | 23.03% | 0.73x | 1.29x | AU$3.82 Million |
| 2009 | 18.75% | 24.28% | 0.67x | 1.15x | AU$2.99 Million |
| 2010 | -5.23% | -13.34% | 0.36x | 1.10x | AU$-4.59 Million |
| 2011 | -0.79% | -1.85% | 0.39x | 1.08x | AU$-3.23 Million |
| 2012 | -6.53% | -18.73% | 0.31x | 1.13x | AU$-4.65 Million |
| 2013 | -20.57% | -50.54% | 0.34x | 1.18x | AU$-7.96 Million |
| 2014 | -25.93% | -49.54% | 0.47x | 1.11x | AU$-9.18 Million |
| 2015 | -7.63% | -19.03% | 0.36x | 1.10x | AU$-6.91 Million |
| 2016 | -9.24% | -52.64% | 0.14x | 1.22x | AU$-8.34 Million |
| 2017 | -1.58% | -8.10% | 0.16x | 1.19x | AU$-5.66 Million |
| 2018 | -52.31% | -131.70% | 0.33x | 1.20x | AU$-20.22 Million |
| 2019 | -24.32% | -50.15% | 0.39x | 1.25x | AU$-8.58 Million |
| 2020 | -8.24% | -13.61% | 0.49x | 1.23x | AU$-4.25 Million |
| 2021 | 7.62% | 13.15% | 0.47x | 1.24x | AU$-658.50K |
| 2022 | -4.36% | -9.58% | 0.40x | 1.13x | AU$-3.82 Million |
| 2023 | -35.20% | -122.54% | 0.25x | 1.17x | AU$-10.91 Million |
| 2024 | -23.09% | -40.93% | 0.42x | 1.34x | AU$-7.76 Million |
| 2025 | -36.84% | -40.79% | 0.54x | 1.69x | AU$-10.25 Million |
Industry Comparison
This section compares IDT Australia Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $29,315,554
- Average return on equity (ROE) among peers: 5445.71%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| IDT Australia Ltd (IDT) | AU$21.89 Million | 7.53% | 0.69x | $12.10 Million |
| Althea Group Holdings Ltd (AGH) | $41.45 Million | -29.25% | 0.36x | $12.05 Million |
| BOD Science Ltd (BOD) | $3.47 Million | -155.95% | 0.53x | $3.01 Million |
| BPH Global Ltd (BP8) | $149.84K | 50079.24% | 22.90x | $2.62 Million |
| Cann Group Ltd (CAN) | $648.33K | -644.19% | 0.12x | $5.62 Million |
| ECS Botanics Holdings Ltd (ECS) | $319.74K | -109.87% | 0.16x | $5.65 Million |
| Ecofibre Ltd (EOF) | $109.94 Million | -13.34% | 0.36x | $5.36 Million |
| Epsilon Healthcare Ltd (EPN) | $2.99 Million | -68.61% | 4.98x | $5.51 Million |
| Elixinol Wellness Ltd (EXL) | $99.42 Million | 0.00% | 0.04x | $2.05 Million |
| Invion Ltd (IVX) | $5.46 Million | -46.66% | 0.11x | $3.70 Million |
About IDT Australia Ltd
IDT Australia Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (API) and finished dose forms (FDF) products in Australia, Asia, Europe, and the United States. The company offers microbiological and analytical testing, clinical packaging, and pharmacy services. It also provides medicinal cannabis and psychedelics; oral finished doses; and ase… Read more